Literature DB >> 17200715

Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members.

Jennifer M MacArthur1, Joseph R Bishop, Kristin I Stanford, Lianchun Wang, André Bensadoun, Joseph L Witztum, Jeffrey D Esko.   

Abstract

We examined the role of hepatic heparan sulfate in triglyceride-rich lipoprotein metabolism by inactivating the biosynthetic gene GlcNAc N-deacetylase/N-sulfotransferase 1 (Ndst1) in hepatocytes using the Cre-loxP system, which resulted in an approximately 50% reduction in sulfation of liver heparan sulfate. Mice were viable and healthy, but they accumulated triglyceride-rich lipoprotein particles containing apoB-100, apoB-48, apoE, and apoCI-IV. Compounding the mutation with LDL receptor deficiency caused enhanced accumulation of both cholesterol- and triglyceride-rich particles compared with mice lacking only LDL receptors, suggesting that heparan sulfate participates in the clearance of cholesterol-rich lipoproteins as well. Mutant mice synthesized VLDL normally but showed reduced plasma clearance of human VLDL and a corresponding reduction in hepatic VLDL uptake. Retinyl ester excursion studies revealed that clearance of intestinally derived lipoproteins also depended on hepatocyte heparan sulfate. These findings show that under normal physiological conditions, hepatic heparan sulfate proteoglycans play a crucial role in the clearance of both intestinally derived and hepatic lipoprotein particles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200715      PMCID: PMC1716206          DOI: 10.1172/JCI29154

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  82 in total

1.  An automated multidimensional protein identification technology for shotgun proteomics.

Authors:  D A Wolters; M P Washburn; J R Yates
Journal:  Anal Chem       Date:  2001-12-01       Impact factor: 6.986

2.  Apoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein E.

Authors:  T Hirano; T Takahashi; S Saito; H Tajima; T Ebara; M Adachi
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-10       Impact factor: 4.310

3.  Lipoprotein lipase in liver. Release by heparin and immunocytochemical localization.

Authors:  S Vilaró; I Ramírez; G Bengtsson-Olivecrona; T Olivecrona; M Llobera
Journal:  Biochim Biophys Acta       Date:  1988-03-25

4.  Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL.

Authors:  J D Horton; H Shimano; R L Hamilton; M S Brown; J L Goldstein
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

5.  Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance.

Authors:  U Olsson; A C Egnell; M R Lee; G O Lundén ; M Lorentzon; M Salmivirta; G Bondjers; G Camejo
Journal:  Diabetes       Date:  2001-09       Impact factor: 9.461

6.  New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E.

Authors:  C P Libeu; S Lund-Katz; M C Phillips; S Wehrli; M J Hernáiz; I Capila; R J Linhardt; R L Raffaï; Y M Newhouse; F Zhou; K H Weisgraber
Journal:  J Biol Chem       Date:  2001-08-10       Impact factor: 5.157

7.  Heparin is essential for the storage of specific granule proteases in mast cells.

Authors:  D E Humphries; G W Wong; D S Friend; M F Gurish; W T Qiu; C Huang; A H Sharpe; R L Stevens
Journal:  Nature       Date:  1999-08-19       Impact factor: 49.962

8.  Heparin-binding defective lipoprotein lipase is unstable and causes abnormalities in lipid delivery to tissues.

Authors:  E P Lutz; M Merkel; Y Kako; K Melford; H Radner; J L Breslow; A Bensadoun; I J Goldberg
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

9.  Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B.

Authors:  S G Young; R S Smith; D M Hogle; L K Curtiss; J L Witztum
Journal:  Clin Chem       Date:  1986-08       Impact factor: 8.327

10.  Heparin decreases the degradation rate of lipoprotein lipase in adipocytes.

Authors:  M Cupp; A Bensadoun; K Melford
Journal:  J Biol Chem       Date:  1987-05-05       Impact factor: 5.157

View more
  93 in total

1.  Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia.

Authors:  H Carlijne Hassing; Hans Mooij; Shuling Guo; Brett P Monia; Keyang Chen; Wim Kulik; Geesje M Dallinga-Thie; Max Nieuwdorp; Erik S G Stroes; Kevin Jon Williams
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

2.  Serglycin protects against high fat diet-induced increase in serum LDL in mice.

Authors:  Astri J Meen; Christian A Drevon; Gunnar Pejler; Trond G Jenssen; Ole Kristoffer Olstad; Magnus Åbrink; Svein O Kolset
Journal:  Glycoconj J       Date:  2015-09-21       Impact factor: 2.916

3.  Atherogenic remnant lipoproteins: role for proteoglycans in trapping, transferring, and internalizing.

Authors:  Robert W Mahley; Yadong Huang
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 4.  LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies.

Authors:  Anna P Lillis; Lauren B Van Duyn; Joanne E Murphy-Ullrich; Dudley K Strickland
Journal:  Physiol Rev       Date:  2008-07       Impact factor: 37.312

5.  A role for a lithium-inhibited Golgi nucleotidase in skeletal development and sulfation.

Authors:  Joshua P Frederick; A Tsahai Tafari; Sheue-Mei Wu; Louis C Megosh; Shean-Tai Chiou; Ryan P Irving; John D York
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-11       Impact factor: 11.205

6.  Novel method for reducing plasma cholesterol: a ligand replacement therapy.

Authors:  G M Anantharamaiah; Dennis Goldberg
Journal:  Clin Lipidol       Date:  2015-01-01

7.  Type 2 diabetes in mice induces hepatic overexpression of sulfatase 2, a novel factor that suppresses uptake of remnant lipoproteins.

Authors:  Keyang Chen; Ming-Lin Liu; Lana Schaffer; Mingzhen Li; Guenther Boden; Xiangdong Wu; Kevin Jon Williams
Journal:  Hepatology       Date:  2010-11-03       Impact factor: 17.425

8.  Altered heparan sulfate structure in mice with deleted NDST3 gene function.

Authors:  Srinivas R Pallerla; Roger Lawrence; Lars Lewejohann; Yi Pan; Tobias Fischer; Uwe Schlomann; Xin Zhang; Jeffrey D Esko; Kay Grobe
Journal:  J Biol Chem       Date:  2008-04-01       Impact factor: 5.157

9.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

10.  The recovery time course of the endothelial cell glycocalyx in vivo and its implications in vitro.

Authors:  Daniel R Potter; John Jiang; Edward R Damiano
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.